Literature DB >> 17703230

Minimizing leakage of value from R&D alliances.

Andrew Jones1.   

Abstract

Alliances, which are a key component of the research and development (R&D) strategies of most major pharmaceutical companies, demand significant management time and resources. There is no doubt that considerable value can be derived from R&D alliances, and much has been written about how companies can maximize such value, but the issue of how the associated risks can be minimized has been neglected in comparison. Here, we summarize recent trends in alliance formation and discuss approaches to minimize risk in alliances, which are growing in importance as alliance activity increases.

Entities:  

Mesh:

Year:  2007        PMID: 17703230     DOI: 10.1038/nrd2357

Source DB:  PubMed          Journal:  Nat Rev Drug Discov        ISSN: 1474-1776            Impact factor:   84.694


  2 in total

1.  The drug lag and associated factors for orphan anticancer drugs in Japan compared to the United States.

Authors:  Hiroki Nakayama; Naoki Matsumaru; Katsura Tsukamoto
Journal:  Invest New Drugs       Date:  2018-05-31       Impact factor: 3.850

2.  The value of royalty.

Authors:  Michael A Reslinski; Bernhard S Wu
Journal:  Nat Biotechnol       Date:  2016-07-12       Impact factor: 54.908

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.